

Spain Cell Therapy Manufacturing Market By Therapy (T-Cell Therapies, Dendritic Cell Therapies, Tumor Cell Therapies, Stem Cell Therapies), By Source of Cell (Autologous v/s Allogenic), By Scale of Operation (Preclinical, Clinical, Commercial), By Source (In-House v/s Contract Manufacturing), By Application (Oncology, Cardiovascular Diseases, Orthopedic Diseases, Others), By End User (Pharmaceutical & Biotechnology Companies, Academic & Research Institutes, Others), By Region, Competition, Forecast & Opportunities, 2019-2029F

Market Report | 2024-12-31 | 87 pages | TechSci Research

AVAILABLE LICENSES:

- Single User License \$3500.00
- Multi-User License \$4500.00
- Custom Research License \$7000.00

Report description:

Spain Cell Therapy Manufacturing Market was valued at USD 152.23 Million in 2023 and is anticipated to reach USD 271.11 Million with a CAGR of 10.09% through 2029. Spain, like many other countries, has seen a growing interest in cell therapy, which involves the use of living cells to treat various medical conditions. This includes therapies such as stem cell therapy, CAR-T cell therapy, and other regenerative medicine approaches. Spain has a strong presence in the field of regenerative medicine and cell therapy research. Many academic institutions and biotechnology companies in the country are actively involved in the development of novel cell therapies.

Key Market Drivers

Strong Research and Development

The cell therapy manufacturing market in Spain is thriving, driven significantly by its robust research and development (R&D) ecosystem. Spain's dedication to regenerative medicine and advanced cell therapy research has positioned it as a leader in groundbreaking scientific discoveries and transformative healthcare solutions.

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Spanish researchers, supported by world-class academic institutions and research hubs such as the Spanish Cell Therapy Network (TerCel), are at the forefront of pioneering work. These centers attract top global talent and foster interdisciplinary collaborations that accelerate innovation in the development of cell-based therapies for conditions like cancer, neurodegenerative disorders, and rare diseases. For example, as per Spain's Ministry of Science and Innovation, Spain ranked among the top EU nations in Horizon Europe R&D funding, showcasing its commitment to cutting-edge medical research.

This vibrant R&D environment has led to the establishment of clinical trials for novel therapies, bridging the gap between laboratory research and market readiness. Regulatory support from the Spanish Agency of Medicines and Medical Devices (AEMPS) ensures rigorous standards for safety and efficacy, facilitating the path from research to commercialization. Spain is noted for streamlining clinical trial applications, a critical step in accelerating cell therapy market entry.

Strong R&D efforts also attract significant investment. Public and private stakeholders recognize the transformative potential of regenerative medicine, resulting in steady funding flows to support research and manufacturing infrastructure. For instance, the EU and Spanish government have allocated substantial funding under programs like PERTE for cutting-edge health technologies, ensuring Spain's leadership in advanced therapeutics.

Spain's collaborative approach extends globally, with Spanish researchers actively engaging in international partnerships, enriching the global body of knowledge while bringing cutting-edge expertise to domestic projects. This global connectivity and commitment to innovation highlight Spain's pivotal role in advancing the cell therapy manufacturing market.

Collaborative Ecosystem

Collaboration is often the catalyst for progress and innovation. In the context of Spain's burgeoning cell therapy manufacturing market, a collaborative ecosystem is proving to be a driving force behind its remarkable growth.

Spain's collaborative ecosystem brings together diverse stakeholders, including academic institutions, biotechnology companies, research centers, and healthcare institutions. By uniting knowledge and expertise from various fields, this ecosystem creates a fertile ground for cross-disciplinary innovation. Researchers and professionals from different backgrounds collaborate to tackle complex challenges and develop cutting-edge cell therapies.

Collaboration is the bridge that accelerates the translation of research findings into practical applications. In Spain, close partnerships between researchers and industry players facilitate the seamless transition from laboratory discoveries to clinical trials and, ultimately, to the manufacturing and commercialization of cell-based therapies. This acceleration significantly shortens the time it takes to bring innovative treatments to patients.

Collaboration allows for the pooling of resources and infrastructure. Research institutions and biotech companies often share costly facilities and equipment, which can be prohibitively expensive for individual entities. This resource-sharing model makes the cell therapy manufacturing process more cost-effective and efficient, which ultimately benefits patients and the industry as a whole.

The collaborative ecosystem in Spain is not only attractive to researchers and organizations but also to investors. A collaborative environment that encourages partnerships and knowledge sharing signals a commitment to innovation and a willingness to work together to overcome challenges. This attracts both public and private investments, which are crucial for funding research, development, and manufacturing efforts.

Collaboration within Spain's cell therapy manufacturing ecosystem extends to the conduct of clinical trials. The pooling of expertise and resources enables the efficient organization and execution of clinical trials, which are essential for evaluating the safety and efficacy of new therapies. The ability to conduct a large number of well-designed trials is a significant asset for the cell therapy market.

Clinical Trials

Clinical trials serve as the cornerstone of Spain's dynamic cell therapy manufacturing market, bridging scientific discovery and therapeutic application. These trials are essential for assessing the safety and efficacy of innovative cell-based treatments, positioning Spain as a leader in advanced healthcare solutions.

Spain hosts a significant number of clinical trials in cell therapy, underscoring its commitment to innovation. According to the Spanish Agency of Medicines and Medical Devices (AEMPS), as of 2023, the country approved 84 clinical trials for advanced therapies, with a substantial portion focused on cell-based treatments. This robust pipeline accelerates the entry of novel therapies into the market while enhancing Spain's reputation as a hub for cutting-edge research.

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

The streamlined regulatory framework established by AEMPS supports efficient clinical trial assessments, enabling researchers to navigate complex protocols with greater ease. This efficiency expedites the commercialization process, ensuring that groundbreaking therapies reach patients sooner. Such an environment not only fosters innovation but also attracts global investment, driving the development of infrastructure and manufacturing capabilities.

Spain's focus on clinical trials provides patients with access to pioneering treatments unavailable through conventional means.

Advanced therapies like CAR-T cell treatments are being trialed, offering hope to individuals with challenging conditions. By participating in these trials, patients benefit from state-of-the-art care while contributing to scientific advancement.

The global sharing of data and findings from Spain's clinical trials reinforces the country's leadership in cell therapy. Insights gained are disseminated across international platforms, fostering collaboration and setting benchmarks in therapeutic innovation.

Spain's strategic emphasis on clinical trials continues to elevate its profile in the global cell therapy landscape, attracting investments, improving healthcare outcomes, and advancing the frontier of medical science.

Key Market Challenges

Cost and Resource Management

The Spain Cell Therapy Manufacturing Market faces significant challenges in cost and resource management, hindering its growth and widespread adoption. Cell therapy manufacturing is an intricate and resource-intensive process involving specialized facilities, skilled personnel, and advanced technologies. The cost associated with establishing Good Manufacturing Practice (GMP)-compliant facilities and maintaining regulatory compliance often represents a substantial financial burden for manufacturers.

Cell therapies, by their nature, require customized production processes tailored to individual patients or small patient cohorts.

This leads to limited economies of scale, further driving up production costs. Additionally, sourcing high-quality raw materials, such as cell lines and reagents, adds another layer of expense. Resource optimization becomes critical, as any inefficiencies in the production process can result in wasted materials and extended timelines. Personnel training and retaining highly skilled professionals also contribute to the financial strain. The labor-intensive nature of cell therapy manufacturing demands expertise in cell biology, biotechnology, and quality assurance, all of which come at a premium cost. Furthermore, the logistical challenges of transporting temperature-sensitive products exacerbate the complexity, requiring robust cold chain management.

Balancing cost constraints while ensuring product quality and scalability remains a pressing challenge. Overcoming these hurdles requires innovative strategies, such as automation, advanced bioprocessing technologies, and public-private partnerships to share financial and resource burdens.

Quality Control and Standardization

Quality control and standardization present a significant challenge in the Spain Cell Therapy Manufacturing Market, posing obstacles to scalability and widespread adoption. Cell therapy manufacturing involves complex biological processes, which can result in variability between batches. Ensuring consistent quality and therapeutic efficacy across products requires robust quality control measures, which are often time-consuming and resource-intensive.

The lack of standardized protocols and guidelines for cell therapy manufacturing exacerbates these challenges. Variations in cell sources, culture conditions, and expansion techniques lead to inconsistencies, making it difficult to maintain uniformity in the final product. Regulatory bodies, such as the Spanish Medicines Agency (AEMPS), emphasize stringent compliance, adding another layer of complexity to the production process.

Analytical techniques for characterizing cell therapy products are still evolving. Current methods may not always detect subtle changes in cell functionality or potency, increasing the risk of suboptimal therapeutic outcomes. Furthermore, ensuring sterility and avoiding contamination during production require highly controlled environments and sophisticated equipment, further driving up costs.

To address these challenges, the industry must invest in developing advanced analytical tools, standardized operating procedures, and collaborative frameworks that align with regulatory requirements. Establishing a harmonized approach to quality control and standardization is essential to enhance product consistency, patient safety, and market scalability.

Key Market Trends

Automation and Robotics

The integration of automation and robotics is revolutionizing the cell therapy manufacturing landscape in Spain, significantly enhancing efficiency, precision, and scalability. Traditional cell therapy production is labor-intensive and prone to human error,

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

leading to variability in product quality. By adopting automated systems and robotic technologies, manufacturers can standardize processes, reduce manual interventions, and maintain consistent product quality. For example, Multiply Labs has developed robotic systems to automate cell therapy manufacturing, addressing production bottlenecks and minimizing contamination risks. Their modular approach facilitates the industrial-scale production of gene-modified cell therapies.

The Spanish government recognizes the importance of automation in advancing the biotechnology sector. Initiatives like the "Industria Conectada 4.0" program promote the adoption of advanced manufacturing technologies, including robotics and automation, to enhance industrial productivity and competitiveness. This strategic focus aligns with the cell therapy manufacturing industry's needs for sophisticated technologies to meet increasing demand and strict regulatory standards. The implementation of automation and robotics offers multiple advantages, such as scalability to meet growing demand, cost efficiency by reducing manual labor and errors, and enhanced quality assurance through consistent adherence to protocols. However, challenges remain, including significant capital investment and the need for specialized technical expertise. Collaborative efforts between technology providers and cell therapy manufacturers are addressing these issues, with developments like vendor-agnostic automation platforms streamlining manufacturing processes across various equipment.

Allogeneic Therapies

Allogeneic therapies, which utilize donor-derived cells for treatment, are gaining prominence in Spain's cell therapy manufacturing sector. Unlike autologous therapies that use a patient's own cells, allogeneic approaches offer the advantage of producing cell batches that can treat multiple patients, enhancing scalability and accessibility.

A notable example is Darvadstrocel (commercially known as Alofisel), an allogeneic cell therapy developed through Spain's collaborative efforts. Supported by the Spanish Cell Therapy Network (TerCel), Darvadstrocel became the first allogeneic cell therapy product approved by the European Medicines Agency (EMA). This achievement underscores Spain's commitment to advancing cell-based treatments and highlights the potential of allogeneic therapies to address complex medical conditions. The Spanish Agency of Medicines and Medical Devices (AEMPS) plays a pivotal role in regulating and promoting clinical trials for advanced therapies, including allogeneic treatments. AEMPS has streamlined procedures to facilitate the assessment of multinational clinical trial applications, thereby accelerating the development of innovative therapies. This regulatory support is crucial for the growth of allogeneic cell therapies in Spain, ensuring that they meet stringent safety and efficacy standards. Spain's focus on allogeneic therapies is further evidenced by the establishment of networks like TerCel, which has been instrumental in boosting translational research in cell therapy over the past 15 years. By fostering public-private collaborations, TerCel has significantly contributed to the development and clinical application of allogeneic cell therapy products, positioning Spain as a leader in this field.

Segmental Insights

Therapy Insights

Based on the therapy, T-Cell therapies emerged as the fastest growing segment in the the Spain cell therapy manufacturing market through 2029. The growing demand for innovative and personalized treatment options has significantly elevated the prominence of T-Cell therapies in the healthcare landscape. These therapies offer promising results in the treatment of various cancers and autoimmune disorders, aligning perfectly with Spain's rising healthcare needs. Also, the country's well-established infrastructure for biopharmaceutical manufacturing, coupled with a robust regulatory framework, provides a conducive environment for the production and distribution of T-Cell therapies. The presence of leading biotech companies and research institutions specializing in cell therapy further enhances Spain's position as a potential industry leader. As a result, the convergence of clinical efficacy, infrastructure, and expertise in T-Cell therapy manufacturing positions it to dominate the Spanish market and contribute significantly to the nation's healthcare ecosystem.

Application Insights

Based on the application, Oncology emerged as the dominant segment in the Spain Cell Therapy Manufacturing Market in 2023. Firstly, the prevalence of cancer in Spain is a significant public health concern, driving a growing demand for innovative and effective treatment options. Cell therapies, particularly CAR-T and T-Cell therapies, have shown remarkable potential in treating various forms of cancer, making them a compelling choice for both patients and healthcare providers. Additionally, the collaboration between research institutions, biotech companies, and academic centers in Spain has fostered an environment conducive to advancing cell therapy technologies specific to oncology. Moreover, the regulatory framework and infrastructure in

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

the country have been well-equipped to support the development, manufacturing, and commercialization of oncology-focused cell therapies. These factors collectively position oncology as a dominant force within the Spain cell therapy manufacturing market, offering both hope for cancer patients and economic opportunities within the biopharmaceutical sector.

Regional Insights

The Central Region of North Spain emerged as the dominant region in the the Spain cell therapy manufacturing market in 2023. Firstly, its strategic geographical location and well-developed transportation infrastructure provide easy access to major cities and ports, facilitating the efficient distribution of cell therapy products. The region also boasts a rich pool of talent, with a skilled workforce and a strong tradition of scientific research and development in the field of life sciences. Additionally, the Central Region's close proximity to renowned research institutions, academic centers, and leading biotech companies creates a dynamic ecosystem that fosters innovation and collaboration. Likewise, the supportive regulatory environment and established manufacturing facilities in this region make it an ideal hub for the production of cutting-edge cell therapies. These factors, combined with a commitment to excellence in healthcare and biopharmaceuticals, position the Central Region of North Spain as a dominant force in the country's cell therapy manufacturing market.

Key Market Players

- Novartis AG
- F.Hoffmann La Roche AG
- Gilead Sciences, Inc
- Thermo Fischer Scientific, Inc
- Catalent, Inc
- Merck KGaA
- Lonza Biologics O Porrino SL
- Charles River Laboratories Espana S.A.
- Fujifilm Holdings Corporation
- AMGEN S.A.

Report Scope:

In this report, the Spain Cell Therapy Manufacturing Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

- Spain Cell Therapy Manufacturing Market, By Therapy:
 - o T-Cell Therapies
 - o Dendritic Cell Therapies
 - o Tumor Cell Therapies
 - o Stem Cell Therapies
- Spain Cell Therapy Manufacturing Market, By Source of Cell:
 - o Autologous
 - o Allogenic
- Spain Cell Therapy Manufacturing Market, By Scale of Operation:
 - o Preclinical
 - o Clinical
 - o Commercial
- Spain Cell Therapy Manufacturing Market, By Source:
 - o In-House
 - o Contract Manufacturing
- Spain Cell Therapy Manufacturing Market, By Application:
 - o Oncology
 - o Cardiovascular Diseases
 - o Orthopedic Diseases
 - o Others

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

□ Spain Cell Therapy Manufacturing Market, By End User:

- o Pharmaceutical & Biotechnology Companies
- o Academic & Research Institutes
- o Others

□ Spain Cell Therapy Manufacturing Market, By Region:

- o Central Region North Spain
- o Aragon & Catalonia
- o Andalusia, Murcia & Valencia
- o Madrid, Extremadura & Castilla

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Spain Cell Therapy Manufacturing Market.

Available Customizations:

Spain Cell Therapy Manufacturing market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

□ Detailed analysis and profiling of additional market players (up to five).

Table of Contents:

1. Service Overview
 - 1.1. Market Definition
 - 1.2. Scope of the Market
 - 1.2.1. Markets Covered
 - 1.2.2. Years Considered for Study
 - 1.2.3. Key Market Segmentations
2. Research Methodology
 - 2.1. Objective of the Study
 - 2.2. Baseline Methodology
 - 2.3. Key Industry Partners
 - 2.4. Major Association and Secondary Sources
 - 2.5. Forecasting Methodology
 - 2.6. Data Triangulation & Validation
 - 2.7. Assumptions and Limitations
3. Executive Summary
 - 3.1. Overview of the Market
 - 3.2. Overview of Key Market Segmentations
 - 3.3. Overview of Key Market Players
 - 3.4. Overview of Key Regions/Countries
 - 3.5. Overview of Market Drivers, Challenges, Trends
4. Voice of Customer
5. Spain Cell Therapy Manufacturing Market Outlook
 - 5.1. Market Size & Forecast
 - 5.1.1. By Value
 - 5.2. Market Share & Forecast
 - 5.2.1. By Therapy (T-Cell Therapies, Dendritic Cell Therapies, Tumor Cell Therapies, Stem Cell Therapies)
 - 5.2.2. By Source of Cell (Autologous v/s Allogenic)
 - 5.2.3. By Scale of Operation (Preclinical, Clinical, Commercial)
 - 5.2.4. By Source (In-House v/s Contract Manufacturing)

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 5.2.5. By Application (Oncology, Cardiovascular Diseases, Orthopedic Diseases, Others)
- 5.2.6. By End User (Pharmaceutical & Biotechnology Companies, Academic & Research Institutes, Others)
- 5.2.7. By Region
- 5.2.8. By Company (2023)
- 5.3. Market Map
 - 5.3.1. By Therapy
 - 5.3.2. By Source of Cell
 - 5.3.3. By Scale of Operation
 - 5.3.4. By Source
 - 5.3.5. By Application
 - 5.3.6. By End User
 - 5.3.7. By Region
- 6. Central Region North Spain Cell Therapy Manufacturing Market Outlook
 - 6.1. Market Size & Forecast
 - 6.1.1. By Value
 - 6.2. Market Share & Forecast
 - 6.2.1. By Therapy (T-Cell Therapies, Dendritic Cell Therapies, Tumor Cell Therapies, Stem Cell Therapies)
 - 6.2.2. By Source of Cell (Autologous v/s Allogenic)
 - 6.2.3. By Scale of Operation (Preclinical, Clinical, Commercial)
 - 6.2.4. By Source (In-House v/s Contract Manufacturing)
 - 6.2.5. By Application (Oncology, Cardiovascular Diseases, Orthopedic Diseases, Others)
 - 6.2.6. By End User (Pharmaceutical & Biotechnology Companies, Academic & Research Institutes, Others)
- 7. Aragon & Catalonia Cell Therapy Manufacturing Market Outlook
 - 7.1. Market Size & Forecast
 - 7.1.1. By Value
 - 7.2. Market Share & Forecast
 - 7.2.1. By Therapy (T-Cell Therapies, Dendritic Cell Therapies, Tumor Cell Therapies, Stem Cell Therapies)
 - 7.2.2. By Source of Cell (Autologous v/s Allogenic)
 - 7.2.3. By Scale of Operation (Preclinical, Clinical, Commercial)
 - 7.2.4. By Source (In-House v/s Contract Manufacturing)
 - 7.2.5. By Application (Oncology, Cardiovascular Diseases, Orthopedic Diseases, Others)
 - 7.2.6. By End User (Pharmaceutical & Biotechnology Companies, Academic & Research Institutes, Others)
- 8. Andalusia, Murcia & Valencia Cell Therapy Manufacturing Market Outlook
 - 8.1. Market Size & Forecast
 - 8.1.1. By Value
 - 8.2. Market Share & Forecast
 - 8.2.1. By Therapy (T-Cell Therapies, Dendritic Cell Therapies, Tumor Cell Therapies, Stem Cell Therapies)
 - 8.2.2. By Source of Cell (Autologous v/s Allogenic)
 - 8.2.3. By Scale of Operation (Preclinical, Clinical, Commercial)
 - 8.2.4. By Source (In-House v/s Contract Manufacturing)
 - 8.2.5. By Application (Oncology, Cardiovascular Diseases, Orthopedic Diseases, Others)
 - 8.2.6. By End User (Pharmaceutical & Biotechnology Companies, Academic & Research Institutes, Others)
- 9. Madrid, Extremadura & Castilla Cell Therapy Manufacturing Market Outlook
 - 9.1. Market Size & Forecast
 - 9.1.1. By Value
 - 9.2. Market Share & Forecast
 - 9.2.1. By Therapy (T-Cell Therapies, Dendritic Cell Therapies, Tumor Cell Therapies, Stem Cell Therapies)

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 9.2.2. By Source of Cell (Autologous v/s Allogenic)
- 9.2.3. By Scale of Operation (Preclinical, Clinical, Commercial)
- 9.2.4. By Source (In-House v/s Contract Manufacturing)
- 9.2.5. By Application (Oncology, Cardiovascular Diseases, Orthopedic Diseases, Others)
- 9.2.6. By End User (Pharmaceutical & Biotechnology Companies, Academic & Research Institutes, Others)
- 10. Market Dynamics
 - 10.1. Drivers
 - 10.2. Challenges
- 11. Market Trends & Developments
 - 11.1. Recent Developments
 - 11.2. Mergers & Acquisitions
 - 11.3. Product Launches
- 12. Policy & Regulatory Landscape
- 13. Porter's Five Forces Analysis
 - 13.1. Competition in the Industry
 - 13.2. Potential of New Entrants
 - 13.3. Power of Suppliers
 - 13.4. Power of Customers
 - 13.5. Threat of Substitute Products
- 14. Spain Economic Profile
- 15. Competitive Landscape
 - 15.1. Novartis AG
 - 15.1.1. Business Overview
 - 15.1.2. Product Offerings
 - 15.1.3. Recent Developments
 - 15.1.4. Financials (As Reported)
 - 15.1.5. Key Personnel
 - 15.1.6. SWOT Analysis
 - 15.2. F.Hoffmann La Roche AG
 - 15.3. Gilead Sciences, Inc
 - 15.4. Thermo Fischer Scientific, Inc
 - 15.5. Catalent, Inc
 - 15.6. Merck KGaA
 - 15.7. Lonza Biologics O Porrino SL
 - 15.8. Charles River Laboratories Espana S.A.
 - 15.9. Fujifilm Holdings Corporation
 - 15.10. AMGEN S.A.
- 16. Strategic Recommendations
- 17. About Us & Disclaimer

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Spain Cell Therapy Manufacturing Market By Therapy (T-Cell Therapies, Dendritic Cell Therapies, Tumor Cell Therapies, Stem Cell Therapies), By Source of Cell (Autologous v/s Allogenic), By Scale of Operation (Preclinical, Clinical, Commercial), By Source (In-House v/s Contract Manufacturing), By Application (Oncology, Cardiovascular Diseases, Orthopedic Diseases, Others), By End User (Pharmaceutical & Biotechnology Companies, Academic & Research Institutes, Others), By Region, Competition, Forecast & Opportunities, 2019-2029F

Market Report | 2024-12-31 | 87 pages | TechSci Research

To place an Order with Scotts International:

- Print this form
- Complete the relevant blank fields and sign
- Send as a scanned email to support@scotts-international.com

ORDER FORM:

Select license	License	Price
	Single User License	\$3500.00
	Multi-User License	\$4500.00
	Custom Research License	\$7000.00
		VAT
		Total

*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

** VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*

Phone*

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>
Zip Code*	<input type="text"/>	Country*	<input type="text"/>
		Date	<input type="text" value="2026-06-09"/>
		Signature	<input type="text"/>